AXT, Inc. enters mid-June with a striking reversal in its short-selling narrative — and an even more striking insider selling cluster that preceded the collapse.
The dominant story this week is what happened at the top of the company's own table. Founder and CEO Morris Young sold over 197,000 shares across June 1–2, collecting roughly $22.3 million at prices between $112 and $114. Lead Independent Director Jesse Chen ran a parallel campaign, offloading more than 15,000 shares across three consecutive sessions at similar levels. The net 90-day insider figure — $40.3 million sold — is not a rounding error for a company of this size. These trades came within days of the stock's peak, and the stock has since fallen 30% in a single week to $78.36. Whether the timing reflects prescience or routine plan-based selling, the optics are difficult to ignore.
The short-interest picture has flipped sharply from the story told in last week's note. Just eight days ago, this column flagged shorts rebuilding toward 15% of the free float with clear directional momentum. That trend has reversed hard. Short interest dropped 18% in a single session on June 9 to 16.4% of the float — down from a peak of nearly 20% earlier in the week, and now running some 18% below where it was seven days ago. Bears appear to be covering into the selloff, not adding. Borrow conditions remain relaxed, with availability at 452% — meaning lenders are still offering roughly four-and-a-half shares for every one borrowed — so there is no mechanical squeeze dynamic at work here. Cost to borrow has edged up 17% on the week to 0.53%, but that is still a near-zero rate in absolute terms. Short covering into a declining stock is the less exciting read; it simply means the pain trade is unwinding.
The options market has also cooled its earlier defensiveness. The put/call ratio is 1.01, essentially flat against its 20-day average of 1.02 and a z-score barely distinguishable from zero. Earlier this month the PCR touched 1.20, the highest level of the past year. That defensive overhang has largely cleared, which is an unusual setup — options traders are not pressing new downside bets even as the stock falls. One explanation: much of the downside has already been priced through the selloff itself.
Analyst targets present a complicated picture given the speed of recent moves. Wedbush maintained its Outperform rating and raised its target to $93 in early May — a constructive call that now looks stretched against a $78 stock, but not wildly so. B. Riley holds a Neutral with a $21 target, a figure that looks stale relative to where the stock has been trading. The mean consensus target of $96.50 implies modest upside from current levels, but that figure was set before the 30% drawdown. The ORTEX short score has eased to 52, down from a peak of 58 midweek, suggesting balanced rather than extreme positioning. Factor scores tell a mixed story: EPS momentum over 90 days ranks in the 99th percentile — the April earnings print showed a 35% one-day pop and a 53% five-day move — but the short score rank sits in just the 9th percentile, indicating the market still views this as a name with meaningful downside risk embedded in the positioning.
Peer context adds texture. AEHR fell 17% on the week and WOLF dropped 20%, suggesting the broader semiconductor materials group is under pressure — AXTI's 29% decline is severe but not entirely idiosyncratic. SMTC held up better, down just 5%.
The next scheduled earnings event is July 30. The key question between now and then is whether the insider selling cluster — which straddled the price peak — draws further scrutiny, and whether short sellers who just covered decide to re-establish positions if the stock stabilises below $80.
See the live data behind this article on ORTEX.
Open AXTI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
